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In the brain, D-amino acid oxidase (DAO/DAAO) mainly oxidizes D-serine, a co-agonist
of the N-methyl-D-aspartate (NMDA) receptors. Thus, DAO can regulate the function
of NMDA receptors via D-serine breakdown. Furthermore, DAO activator (DAOA)/G72
has been reported as both DAOA and repressor. The co-expression of DAO and DAOA
genes and proteins in the human brain is not yet elucidated. The aim of this study
was to understand the regional and age span distribution of DAO and DAOA (mRNA
and protein) in a concomitant manner. We determined DAO and DAOA mRNA and
protein expression across six brain regions in normal human post-mortem brain samples
(16 weeks of gestation to 91 years) using quantitative real-time reverse transcription-
polymerase chain reaction and enzyme-linked immunosorbent assay. We found higher
expression of DAO mRNA in the cerebellum, whereas lower expression of DAO protein
in the cerebellum compared to the other brain regions studied, which suggests post-
transcriptional regulation. We detected DAOA protein but not DAOA mRNA in all brain
regions studied, suggesting a tightly regulated expression. To understand this regulation
at the transcriptional level, we analyzed DNA methylation levels at DAO and DAOA CpG
sites in the cerebellum and frontal cortex of control human post-mortem brain obtained
from Gene Expression Omnibus datasets. Indeed, DAO and DAOA CpG sites in the
cerebellum were significantly more methylated than those in the frontal cortex. While
investigating lifespan effects, we found that DAO mRNA levels were positively correlated
with age <2 years in the cerebellum and amygdala. We also detected a significant
positive correlation (controlled for age) between DAO and DAOA protein in all of the brain
regions studied except for the frontal cortex. In summary, DAO and DAOA expression in
the human brain are both age and brain region dependent.
Keywords: DAO/DAAO, DAOA/G72, gene and protein expression, DNA methylation, human post-mortem brain
regions
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INTRODUCTION
Brain development is a continuous process which extends from
the prenatal period into adulthood (Rapoport et al., 2012).
Abnormal neurodevelopmental processes are implicated in many
psychiatric disorders such as schizophrenia, attention deficit
hyperactivity disorder, autism spectrum disorder, and intellectual
disability (Rapoport et al., 2012; Miller et al., 2016). Moreover,
altered gene expression across different brain regions and lifespan
has been reported in psychiatric disorders (Sibille, 2013; Darby
et al., 2016). For example, schizophrenia risk genes are reported
to be associated with transcripts which are either enriched in
specific brain regions or unique to the human brain, and some
also show preferential expression in the fetal brain (Kang et al.,
2011; Kleinman et al., 2011). Therefore, it is important to analyze
the brain region-specific expression of risk genes for psychiatric
disorders in the normal human brain across the lifespan to
understand the mechanisms underlying pathological changes in
psychiatric disorders.
D-amino acid oxidase (DAO/DAAO; from now on addressed
as DAO) is a flavoenzyme, which oxidizes D-amino acids. Its
main substrate in the brain is D-serine (Pollegioni et al., 2007;
Sacchi et al., 2012). D-serine is a co-agonist of N-methyl-D-
aspartate (NMDA) receptors. In addition to glutamate, NMDA
receptors require a co-agonist (glycine or D-serine) binding at
the glycine modulatory site in order to function normally. D-
serine is shown to be more potent in binding to NMDA receptors
than glycine (Matsui et al., 1995; Shleper et al., 2005; Sacchi
et al., 2012). Thus, DAO can regulate the function of NMDA
receptors via D-serine breakdown, which may lead to NMDA
receptor hypofunction (Kantrowitz and Javitt, 2010; Labrie and
Roder, 2010; Verrall et al., 2010; Labrie et al., 2012). One of the
possible explanations for NMDA receptor hypofunction theory
proposed in schizophrenia is probably an increased activity of
DAO leading to decreased D-serine. DAO activator (DAOA)/G72
(from now on addressed as DAOA) binds to DAO, but the effect
of DAOA on DAO is controversial. This is because DAOA is
reported to both increase (Chumakov et al., 2002; Chang et al.,
2014) and decrease (Sacchi et al., 2008, 2011) the activity of DAO.
DAOA is localized in mitochondria and reported to modulate
its function (Kvajo et al., 2008; Sacchi et al., 2011; Otte et al.,
2014). Thus, the exact function of DAOA is not yet completely
understood.
The human DAO gene located on chromosome 12q24
encodes for a ∼39 kDa protein (Almond et al., 2006; Sacchi
et al., 2008; Verrall et al., 2010) and the human DAOA gene
encodes for a ∼20 kDa protein (Benzel et al., 2008). The genes
DAOA/G30 overlap and are transcribed from opposite strands
on chromosome 13q33. The polymorphisms of these genes
in non-coding regions have been described to be associated
with the pathophysiology of schizophrenia and bipolar disorder
(Detera-Wadleigh and McMahon, 2006; Korostishevsky et al.,
2006; Corvin et al., 2007; Prata et al., 2008; Mossner et al.,
2010; Labrie et al., 2012; Gatt et al., 2015; Liu et al., 2016).
However, a recent genome-wide association study conducted
by the Psychiatric Genomics Consortium found that out of
108 schizophrenia-associated loci, none were within DAO and
DAOA gene regions (Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014). There are several
lines of evidence showing regional and cellular expression of
DAO mRNA and protein in the human brain (Kapoor et al.,
2006; Verrall et al., 2007; Habl et al., 2009; Ono et al., 2009),
however, none of these studies isolated mRNA and protein
concomitantly from the same brain tissue as we did in this
study. On the other hand, the reports of DAOA mRNA and
protein expression in the human brain remain unconvincing
to date. Studies showing DAOA mRNA expression in the
human brain are limited (Chumakov et al., 2002; Korostishevsky
et al., 2006). Moreover, the expression of DAOA mRNA and
protein in the human brain has been questioned (Benzel
et al., 2008; GTEx Consortium, 2015). The human protein
atlas detected DAOA protein (also known as pLG72, from now
on addressed as DAOA) in the cerebellum and the cerebral
cortex (Uhlen et al., 2015). Thus, the regulation of DAO
and DAOA expression in the human brain has not yet been
elucidated.
Furthermore, since DNA methylation can lead to both
increases and decreases in gene expression (Wagner et al.,
2014), it may play a crucial role in the regulation of normal
brain development (Fan et al., 2001). Hannon et al. (2015)
quantified DNA methylation using Illumina 450K array in
normal human post-mortem brain, and reported that DNA
methylation levels in cortical regions differ from the cerebellum.
Moreover, epigenetic regulation of gene expression is very
important in the human brain (Graff et al., 2011; Numata
et al., 2012). However, the extent to which DNA methylation
or other epigenetic modifications affect the expression of genes
important for human brain function, such as DAO/DAOA, is
largely unknown.
In the present study, our main aim was to understand
concomitant DAO and DAOA mRNA and protein expression
in the normal human post-mortem brain during development
and aging in six brain regions. We also correlated DAO mRNA
and DAO protein as well as DAO protein and DAOA protein
to understand their concomitant expression in different brain
regions. Furthermore, we assessed the potential effect of DAO
and DAOA polymorphisms on DAO and DAOA expression
levels to elucidate their role in the regulation of DAO and
DAOA expression. To understand the hypothesized regulation
of DAO and DAOA expression at the transcription level in
an indirect manner, we determined the DNA methylation
levels at CpG sites of DAO and DAOA genes in the
cerebellum and the frontal cortex of control human post-
mortem brain obtained from Gene Expression Omnibus (GEO)
datasets.
MATERIALS AND METHODS
Subjects
Human post-mortem brain samples from six brain regions
were studied. These brain samples were from 55 subjects
with age ranging from 16 weeks of gestation to 91 years,
who had no history of psychiatric or neurological illness, and
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their post-mortem brain samples showed no neuropathological
evidence of any neuropsychiatric disorder. The brain samples
were collected from six brain regions, namely: the cerebellum
(n = 47), brainstem (n = 49), amygdala (n = 47), striatum
(n = 52), thalamus (n = 52), and frontal cortex (n = 54).
These brain samples were procured from the Department of
Neuropathology, Institute of Pathology, University of Würzburg,
Germany (member of the BrainNet Europe-BNEII) and the
London Neurodegenerative Diseases Brain Bank, UK. Informed
written consent for tissue donation was obtained from the
individuals or the next of kin. The causes of death of the study
population are presented in Supplementary Table S6. This study
was approved by the Cantonal Ethic Commission of Zurich (Ref.
Nr. EK: KEK-ZH-Nr. 2013-0177).
DNA, RNA, and Protein Isolation
DNA, RNA, and protein were simultaneously isolated from
the same frozen human post-mortem brain samples using
AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Switzerland).
Firstly, frozen brain tissue samples weighing around 27–34 mg
were disrupted and homogenized in the buffer provided
in the kit using the TissueLyser II (Qiagen, Switzerland).
Secondly, tissue lysates were added to the AllPrep DNA
spin column, and DNA was eluted. Thirdly, RNA was eluted
after adding an ethanol treated sample to a RNeasy spin
column. Finally, proteins in the sample were precipitated
and pelleted by centrifugation. Since the buffer provided in
the kit interferes with protein determination and does not
dissolve proteins completely, protein eluates were acetone
precipitated, and precipitated proteins were redissolved in
urea buffer (7 M urea, 2 M thiourea, 2% CHAPS, and trace
bromophenol, pH 8).
TaqMan SNP Genotyping
DNA isolated from post-mortem human cerebellum (n = 46),
striatum (n = 2), thalamus (n = 5), and amygdala (n = 2) were
used for genotyping. DNA concentrations, A260/A280, and
A260/A230 ratios were measured using a spectrophotometer
(NanoVue Plus, GE Healthcare Life Sciences). Real-time
polymerase chain reaction (PCR) was used to genotype
DAO (rs3918347, rs4623951), and DAOA (rs778293,
rs3916971, rs746187) polymorphisms. These single-nucleotide
polymorphisms (SNPs) were chosen based on previously
reported association with schizophrenia (Allen et al., 2008).
DNA, TaqMan
R©
Genotyping Master Mix (Applied Biosystems,
USA), and SNP Genotyping Assays (rs778293 assay number:
C_8704507_10; rs3916971 assay number: C_27495752_10;
rs746187 assay number: C_1925241_10; rs3918347 assay
number: C_27937201_10; and rs4623951 assay number:
C_32177440_10, all from Applied Biosystems, USA) were
combined in a 384-well plate. Real-time PCR was performed
in a C1000TM CFX384TM Thermal cycler (Bio-Rad) using
TaqMan
R©
SNP Genotyping Assay PCR standard protocol.
Genotypes were determined by the allelic discrimination
program of Bio-Rad CFX ManagerTM Software version 2.1.
The Hardy–Weinberg equilibrium (HWE) p-value and allele
frequencies were computed using PLINK software (Purcell
et al., 2007), and p < 0.05 was considered as statistically
significant.
Quantification of DAO and DAOA mRNA
Levels Using qRT-PCR
RNA isolated from post-mortem human cerebellum (n = 44),
brainstem (n = 40), amygdala (n = 39), striatum (n = 35),
thalamus (n = 37), and frontal cortex (n = 36) were used
for quantitative real-time reverse transcription-PCR (qRT-
PCR). A spectrophotometer (NanoVue Plus, GE Healthcare
Life Sciences) was used to measure RNA concentrations,
A260/A280, and A260/A230 ratios. RNA integrity was
analyzed using Experion automated electrophoresis system
(Bio-Rad, Switzerland) in a subset of samples. RNA (500 ng)
was reverse transcribed using iScriptTM cDNA Synthesis
Kit (Bio-Rad, Switzerland) as per manufacturer’s protocol.
In a subset of samples, negative controls were prepared
with RNA without reverse transcriptase enzyme. qRT-
PCR was performed using cDNA, QuantiFast SYBR Green
PCR kit (Qiagen, Switzerland), 1 µM forward and reverse
DAO primers (Microsynth, Switzerland), and reference
genes [β-actin (ACTB) (QT01680476), aminolevulinate
synthetase (ALAS1) (QT00073122), ribosomal protein L13a
(RPL13A) (QT00089915), alanyl-tRNA synthetase (AARS)
(QT00054747), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (QT01192646), peptidylprolyl isomerase A (PPIA)
(QT00866137), ribosomal RNA (R18S) (QT00019936), and
X-prolyl aminopeptidase 1 (XPNPEP1) (QT00051471); all from
Qiagen, Switzerland]. These eight reference genes were selected
based on previous reports of their stability in human post-
mortem brain (Durrenberger et al., 2012). The DAO primers
used in this study have been described by Verrall et al. (2007)
(forward primer: CGCAGACGTGATTGTCAACT; reverse
primer: GGATGATGTACGGGGAATTG). DAO mRNA levels
were normalized to the reference genes. PCR efficiencies were
calculated using LinRegPCR program (Ruijter et al., 2009)
and mean PCR efficiencies for all studied amplicons were
found to be between 88 and 95%. Normalized DAO mRNA
levels were quantified by importing qRT-PCR quantification
cycle (Cq) values of the gene of interest and reference genes
across brain regions and lifespan into qBASE plus software
(Biogazelle, Belgium) which utilizes gene-specific amplification
efficiencies, and allows normalization with multiple reference
genes. The qBASE plus software automatically selects multiple
stably expressed reference genes in the samples across brain
regions and lifespan by taking into account their stability. The
software carries out a normalization of the gene of interest
with multiple reference genes, ultimately producing calibrated
normalized relative quantities of the gene of interest which
was used to perform statistical analysis (Hellemans et al.,
2007). To detect DAOA mRNA in human post-mortem brain,
qRT-PCR was performed using several different primers for
DAOA gene described by Benzel et al. (2008), Cheng et al.
(2014), and pre-designed primers [QT00058863 (Qiagen),
Hs.PT.58.555086 (IDT), 4331182 (Thermo Fisher Scientific),
qHsaCEP0024792 (Bio-Rad)]. As a positive control, these
primers were also tested on the cDNA prepared from human
Frontiers in Neuroanatomy | www.frontiersin.org 3 April 2017 | Volume 11 | Article 31
fnana-11-00031 April 4, 2017 Time: 15:3 # 4
Jagannath et al. Expression of DAO and DAOA in the Human Brain
neuroblastoma cells (SK-N-SH and SH-SY5Y) overexpressing
DAOA, and these primers detected DAOA mRNA in these
cells, but not in the human post-mortem brain samples (data
not shown). DAOA mRNA was still undetectable in human
post-mortem brain after increasing the cDNA amounts in
qRT-PCR. Furthermore, amplification using QuantiTect Whole
Transcriptome Kit (207043, Qiagen) followed by qRT-PCR to
detect DAOA mRNA levels was not successful. In summary,
we were unable to quantify DAOA mRNA levels with any
of the aforementioned methods in human post-mortem
brain.
Quantification of DAO and DAOA Protein
Levels Using Commercially Available
ELISA Kits
Protein isolated and acetone-precipitated from post-mortem
human cerebellum (n = 40), brainstem (n = 47), amygdala
(n = 46), striatum (n = 48), thalamus (n = 48), and
frontal cortex (n = 54) were used for enzyme-linked
immunosorbent assay (ELISA). Total protein concentration
was quantified using the Bradford assay (Sigma-Aldrich;
Bradford, 1976). DAO and DAOA protein concentrations
were quantified using a commercially available DAO ELISA
kit (SEJ298Hu; Cloud-Clone Corp.) with a high specificity
and a sensitivity of 0.56 ng/mL and a commercially available
DAOA ELISA kit (SEJ297Hu; Cloud-Clone Corp.) with a
high specificity and a sensitivity of 0.061 ng/mL according
to the manufacturer’s instructions. A standard curve was
obtained by plotting absorbance versus different concentration
of protein standards provided with the kit, and DAO and
DAOA protein concentrations were determined from
the standard curve. Normalized DAO and DAOA protein
concentrations were calculated by dividing DAO and DAOA
protein concentrations by the total protein concentration
measured using Bradford assay. The specificity of DAO
and DAOA ELISA kits was proved using sodium dodecyl
sulfate polyacrylamide gel electrophoresis and Western
blotting which is described in detail in Supplementary
Methods S1.
DNA Methylation Levels across DAO and
DAOA CpG Sites in the Cerebellum and
Frontal Cortex
The processed and normalized methylation beta values from
two datasets: GEO accession number GSE61431 as described in
the study of Pidsley et al. (2014) and GSE63347 as described
by Horvath et al. (2015) were downloaded from the GEO
website1. From these datasets, the methylation beta values for
DAO and DAOA CpG sites from the cerebellum and frontal
cortex of controls were extracted.DAO (cg03868278, cg22621535,
cg22801690) and DAOA (cg00809502) CpG sites in the repeat
masker region sites were excluded from the analysis. DAO
CpG sites: cg01694331, cg25362648, cg18037826, cg12592321
lie in the exon 1 and cg26725638 in the exon 2 of DAO
1http://www.ncbi.nlm.nih.gov/geo/
gene. DAOA CpG sites: cg22773522, cg25623522, cg01297020
are in the promoter region, cg13846327 and cg20888753 in
the intron 2, and cg11374446 in the intron 3 region of the
DAOA gene. In the GSE61431 dataset, there were 23 control
cerebellum and frontal cortex samples ranging from ages 25
to 96 years. In the GSE63347 dataset, there were nine control
cerebellum samples in the ages between 38 and 64 years
and 17 control frontal cortex samples between ages 32 and
64 years.
Statistical Analysis
IBM
R©
SPSS
R©
Statistics (version 21) software was used for
statistical analysis. Shapiro–Wilk test with Lilliefors significance
correction was used to assess the normality of the distribution
of mRNA, protein expression, and DNA methylation data.
DAO mRNA, DAO and DAOA protein expression, and
DNA methylation data showed both normal and non-normal
distribution across different brain regions. In order to maintain
consistency between statistical evaluations, non-parametric tests
were used even for normally distributed data. Linear regression
with brain regions as dummy variables was used after a
logarithmic transformation of the non-normally distributed data
to determine the differences in DAO mRNA, DAO and DAOA
protein expression in the brain regions studied; p < 0.05 was
taken as statistically significant. The differences in DAO mRNA,
and DAO and DAOA protein levels across different age groups
were assessed by the Kruskal–Wallis test followed by pair-wise
comparisons with the Mann–Whitney test by adjusting p-value
based on the number of comparisons (Bonferroni correction,
p < 0.005). As we do not have post-mortem brain samples
from ages 2 to 20 years, we divided the ages for correlation
into two groups, namely less than 2 years and more than 20
years. Then, Spearman’s rank correlation test was used to assess
the correlation between age groups (<2 years and >20 years)
and DAO mRNA, DAO and DAOA protein levels; p < 0.05
was taken as statistically significant. We correlated DAO mRNA
with DAO protein levels, and DAO protein levels with DAOA
protein levels across six brain regions by controlling for age using
partial correlation, p < 0.05 was taken as statistically significant.
To analyze the effect of DAO and DAOA SNP genotypes on
DAO mRNA, DAO and DAOA protein expression, analysis of
covariance (ANCOVA) with age as a covariate was used after
a logarithmic transformation of not normally distributed DAO
mRNA and DAOA protein expression data and the inverse
transformation of the non-normally distributed DAO protein
expression data; p < 0.05 was taken as statistically significant.
The differences in methylation levels between the cerebellum and
frontal cortex at each CpG site was assessed using the Mann–
Whitney test by adjusting p-value based on a number of CpG
sites analyzed (Bonferroni correction, p< 0.005). The correlation
between age and methylation levels at each CpG site in the
cerebellum and frontal cortex was assessed using Spearman’s
rank correlation test, and p < 0.05 was considered statistically
significant. GraphPad Prism software (version 6.01) was used to
plot the graphs. The post hoc power analyses for DAO mRNA,
DAO and DAOA protein expression across five age groups were
conducted using G*Power software (Faul et al., 2009), the effect
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sizes were determined from means of age groups, and the alpha
level was set at 0.05 (Supplementary Table S7).
RESULTS
DAO and DAOA Expression in Different
Brain Regions
The current study aimed to assess brain region-specific DAO
and DAOA expression across the lifespan in normal human
post-mortem brain using qRT-PCR and ELISA techniques.
The human post-mortem brain samples were obtained from
55 subjects with no clinical or neuropathological evidence
of neuropsychiatric disorders. The demographic characteristics
of the study sample across five age groups are presented in
Supplementary Table S1. In order to assess any confounding
factors inherent in human post-mortem studies, we addressed
factors such as post-mortem interval (PMI) and gender. The
length of PMI did not differ significantly between different
age groups as assessed by the Kruskal–Wallis test. Gender had
a significant effect on DAO mRNA (p = 0.048) and protein
(p = 0.047) expression in the thalamus and frontal cortex,
respectively (Mann–Whitney test, p < 0.05). DAO mRNA in
the thalamus and DAO protein in the frontal cortex was
significantly more expressed in males than in females. Gender
had no significant effect on DAOA protein expression in all brain
areas studied. There was no statistically significant correlation
between PMI and DAO mRNA, DAO and DAOA protein
levels in the studied brain regions (Spearman’s rank correlation,
p> 0.05).
With the aim of investigating brain region-specific patterns
of DAO and DAOA, we assessed their expression in the normal
brain. We found that DAO mRNA was significantly more
expressed in the cerebellum (set to 100%), followed by the
brainstem (17.6%), thalamus (4.8%), striatum (2.5%), amygdala
(0.9%), and the frontal cortex (0.7%) as assessed by linear
regression (Figures 1A,B). In contrast to DAO mRNA, DAO
protein was significantly less expressed in the cerebellum than
in the remaining brain regions. In the amygdala (set to 100%),
DAO protein was significantly more expressed than in the
brainstem (79.2%; Figure 1C). DAOA protein was significantly
more expressed in the frontal cortex (set to 100%) than in
the cerebellum (65.2%), amygdala (80.4%), and the thalamus
(69.6%). In the striatum (set to 100%), DAOA protein was
significantly more expressed than in the amygdala (66.7%)
and the cerebellum (54.1%). DAOA protein was significantly
less expressed in the thalamus (57.7%) than in the brainstem
(85.6%) and striatum (set to 100%; Figure 1D). Thus, DAO and
DAOA exhibit region-specific expression patterns in the human
brain.
Expression of DAO mRNA, DAO and
DAOA Protein across Lifespan in Six
Brain Regions
The expression patterns across lifespan were analyzed using
two approaches. The first approach was by grouping ages into
five groups, while the second approach was by correlating
ages with expression levels which provided information on
expression patterns during brain development, maturation, and
degeneration. We assessed DAO and DAOA expression across
age groups in six brain regions to understand critical and sensitive
periods during brain development. As the sample size in each
age group was small, we performed a power analysis which
showed reasonable power (>0.76) in the cerebellum, striatum,
and thalamus for DAO mRNA as well as reasonable power
(>0.64) in the cerebellum, striatum, and frontal cortex for DAO
protein, but the power was too low in the brain regions studied
for DAOA protein to conduct statistical analysis (Supplementary
Table S7).
We found statistically significant (p < 0.05) differences
in DAO mRNA levels across the five different age groups,
as assessed by the Kruskal–Wallis test, in the cerebellum,
brainstem (Figure 2B), amygdala, striatum, and thalamus.
However, differences in DAO mRNA levels were found to be
statistically non-significant in the frontal cortex (Figure 2F).
Pair-wise comparisons using the Mann–Whitney test showed
statistically significant differences (p < 0.005) in DAO mRNA
levels between age groups 0–2 years and >61 years in the
cerebellum (Figure 2A) and striatum (Figure 2D), between
prenatal and>61 years in the amygdala (Figure 2C), and between
prenatal and>61 years, 0–2 years and 36–60 years, 0–2 years and
>61 years in the thalamus (Figure 2E).
The differences in DAO protein levels across the five
different age groups was found to be statistically significant
(p < 0.05), as assessed by the Kruskal–Wallis test, in the
cerebellum (Figure 3A), striatum (Figure 3D), and frontal
cortex (Figure 3F). However, differences in DAO protein levels
were found to be statistically non-significant in the brainstem
(Figure 3B), amygdala (Figure 3C), and thalamus (Figure 3E).
Pair-wise comparisons with the Mann–Whitney test showed
statistically significant differences (p < 0.005) in DAO protein
levels for age groups >61 years versus prenatal and 0–2 years
in the frontal cortex (Figure 3F). The differences in DAOA
protein levels across the five different age groups were found to
be statistically significant (p < 0.05) in the brainstem as assessed
by the Kruskal–Wallis test. There were no statistically significant
differences in DAOA protein levels in the cerebellum, amygdala,
striatum, thalamus, and frontal cortex (Figure 4). The specificity
of DAO and DAOA ELISA kits was demonstrated by Western
blot as presented in Supplementary Figure S2.
Using the second approach, we correlated age (<2 years and
>20 years) with DAO and DAOA expression across different
brain regions to understand the critical developmental period
and brain region in DAO and DAOA expression. We found
a statistically significant positive correlation (p < 0.05) as
assessed by Spearman’s rank correlation test, between age less
than 2 years and DAO mRNA levels in the cerebellum and
amygdala (Table 1). Furthermore, there was a significant positive
correlation (Spearman’s rank correlation, p < 0.01) between
age more than 20 years and DAO protein concentration in the
frontal cortex (Table 1). There was no statistically significant
correlation between age and DAOA protein concentration in the
brain regions studied (Table 1).
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FIGURE 1 | DAO mRNA, DAO and DAOA protein levels quantified in six regions of human post-mortem brain. (A) Normalized DAO mRNA levels across
six brain regions. (B) For clarity, this figure focuses only on amygdala, striatum, thalamus, and frontal cortex results presented in panel (A). DAO protein levels
(µg DAO/mg total protein) (C) and DAOA protein levels (µg DAOA/mg total protein) (D) in studied brain regions. Values are presented as box and whisker plots,
whiskers represent minimum to maximum values, “+” indicates mean values, and ∗p < 0.05. Linear regression with brain regions as dummy variables was used after
logarithmic transformation of non-normally distributed data.
Correlation between DAO mRNA, DAO
and DAOA Protein in Different Brain
Regions
In order to assess whether there is a concomitant expression
of DAO mRNA and its protein, we correlated the two in
various brain regions. We did not find any statistically significant
correlation (partial correlation controlled for age) between DAO
mRNA and DAO protein in each of the studied brain regions
(Supplementary Figure S3).
As we concomitantly measured DAO and DAOA proteins
in the human brain, we examined whether these two proteins
correlate in each brain region. A statistically significant positive
correlation (partial correlation controlled for age) was found
between DAO and DAOA protein expression in the cerebellum
[r(36) = 0.74, p < 0.0001; Figure 5A], the brainstem
[r(43)= 0.84, p< 0.0001; Figure 5B], the amygdala [r(36)= 0.88,
p < 0.0001; Figure 5C], the striatum [r(43) = 0.84, p < 0.0001;
Figure 5D], and the thalamus [r(44) = 0.91, p < 0.0001;
Figure 5E]. However, there was no statistically significant
correlation between DAO and DAOA protein concentration in
the frontal cortex [r(49)= 0.27, p= 0.06; Figure 5F].
DAO and DAOA Expression across DAO
and DAOA SNP Genotypes in Different
Brain Regions
We assessed the potential effect of DAO and DAOA SNPs
on DAO and DAOA expression to understand whether such
genetic variations known to be risk factors in schizophrenia
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FIGURE 2 | DAO mRNA levels across five different age groups in six regions of human post-mortem brain (A–F). Data presented as scatter plots.
Kruskal–Wallis test followed by pairwise comparisons with the Mann–Whitney test (∗p < 0.005) was performed to assess the differences in DAO mRNA levels
between different age groups across six brain regions.
FIGURE 3 | DAO protein levels (µg DAO/mg total protein) across different age groups in six regions of human post-mortem brain (A–F). Data presented
as scatter plots. Differences in DAO protein levels across different age groups was assessed by the Kruskal–Wallis test followed by pairwise comparisons with the
Mann–Whitney test (∗p < 0.005).
play a role in the regulation of their expression. The DAO and
DAOA SNPs were in HWE (p > 0.05), and the minor allele
frequency (MAF) of DAO and DAOA SNPs were similar to
HapMap CEU MAF (Supplementary Table S2). In the thalamus,
DAO mRNA was significantly more expressed in rs3918347
DAO genotype GG (minor allele G) than in rs3918347 DAO
genotypes (GA, AA), and DAO mRNA was less expressed in
rs3918347 DAO genotypes GG + GA than in rs3918347 DAO
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FIGURE 4 | DAOA protein expression (µg DAOA/mg total protein) across five different age groups in six regions of human post-mortem brain (A–F).
Values are presented as scatter plots. Differences in DAOA protein levels across different age groups were assessed with the Kruskal–Wallis test.
genotype AA as assessed by ANCOVA with age as covariate
(Supplementary Table S3). However, for the DAO protein, no
statistically significant difference was detected among rs3918347
and rs4623951 DAO genotypes (Supplementary Table S4). For
DAOA protein expression, there was a significantly higher
expression in rs3916971 DAOA genotype TT (minor allele T)
than in rs3916971 DAOA genotypes (CT, CC, CT + CC) in
the amygdala, as assessed by ANCOVA with age as a covariate
(Supplementary Table S5). Nonetheless, from our findings, we
cannot conclusively comment on the effect of DAO and DAOA
SNPs on their expression due to their rather small sample
size.
DNA Methylation across DAO and DAOA
CpG Sites in Cerebellum and Frontal
Cortex
From our DAO and DAOA mRNA and protein findings,
we hypothesized a possible regulation of their expression at
the transcriptional levels. To elucidate this, we analyzed in
silico DNA methylation across DAO and DAOA CpG sites
in the cerebellum and frontal cortex to indirectly explain the
differential DAO and DAOA expression in the human brain. In
GSE61431 and GSE63347 datasets, gender had no statistically
significant effect on DNA methylation levels at DAO and
DAOA CpG sites in the cerebellum and frontal cortex (Mann–
Whitney test, p > 0.005). In GSE61431 and GSE63347 datasets,
DAO CpG site cg18037826 is significantly more methylated
in the cerebellum than in the frontal cortex as assessed by
the Mann–Whitney test, p < 0.001 (Supplementary Figure
S1A). In the GSE61431 dataset, all studied DAOA CpG sites
except cg13846327 are statistically significantly (p < 0.001)
more methylated in the cerebellum than in the frontal cortex
(Supplementary Figure S1B). In GSE63347 dataset, DAOA CpG
sites cg22773522, cg20888753, and cg11374446 are significantly
more methylated in the cerebellum than in the frontal cortex
(Supplementary Figure S1B). There was no statistically significant
correlation between age and DNA methylation levels at DAO and
DAOA CpG sites in the cerebellum and frontal cortex in both
studied datasets.
DISCUSSION
This study investigated the age-span expression of DAO and
DAOA mRNA and protein in six brain regions of normal human
post-mortem brain samples. In this study, we also determined
in silico DNA methylation levels at DAO and DAOA CpG sites
in the cerebellum and frontal cortex of control human post-
mortem brain. The results of this study have implications for
understanding the regulation and expression of DAO and DAOA
genes in the normal human brain during development and
aging.
In this study, DAO mRNA and protein was detected in
all brain regions studied. DAO mRNA was highly expressed
in the cerebellum as compared to the other brain regions
studied. This finding is in line with previous studies of DAO
expression in the human brain (Kapoor et al., 2006; Verrall
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TABLE 1 | Correlation between age and DAO mRNA, DAO and DAOA protein expression across brain regions of human post-mortem brain.
Brain regions Age in years
Prenatal and 0–2 years 20–91 years
N Spearman’s rank
correlation co-efficient
p-value N Spearman’s rank
correlation co-efficient
p-value
Normalized DAO mRNA
levels
Cerebellum 12 0.828 0.001∗∗ 32 0.127 0.488
Brainstem 11 0.310 0.354 29 0.117 0.546
Amygdala 13 0.669 0.017∗ 26 0.261 0.198
Striatum 9 0.008 0.983 26 0.259 0.202
Thalamus 10 0.427 0.218 27 0.254 0.200
Frontal cortex 11 0.352 0.288 25 0.022 0.918
Relative DAO protein
concentration
(µg DAO/mg total protein)
Cerebellum 12 −0.495 0.102 27 −0.143 0.478
Brainstem 16 0.092 0.736 31 0.077 0.679
Amygdala 16 −0.122 0.652 30 0.162 0.392
Striatum 18 0.082 0.747 30 0.142 0.455
Thalamus 20 0.285 0.224 28 0.180 0.359
Frontal cortex 21 0.185 0.422 33 0.482 0.004∗
Relative DAOA protein
concentration
(µg DAOA/mg total protein)
Cerebellum 13 0.120 0.695 27 0.099 0.623
Brainstem 16 0.332 0.210 30 0.324 0.081
Amygdala 13 0.318 0.268 26 0.306 0.121
Striatum 19 0.037 0.879 29 −0.120 0.536
Thalamus 20 0.195 0.411 27 0.021 0.916
Frontal cortex 20 −0.200 0.398 32 0.149 0.417
∗p < 0.05; ∗∗p < 0.01.
et al., 2007; GTEx Consortium, 2015). This is the first study
which quantified DAO protein in human post-mortem brain
using the quantitative ELISA method. Previous studies detected
DAO protein in the human brain using methods such as
immunohistochemistry and Western blot (Bendikov et al., 2007;
Verrall et al., 2007; Uhlen et al., 2015). Immunohistochemical
studies measured DAO immunoreactivity in the human brain
and found that DAO protein was robustly detected both in
the cerebellum and cerebral cortex (Verrall et al., 2007; Uhlen
et al., 2015). Another study detected DAO protein in the
frontal cortex and hippocampus using Western blot (Bendikov
et al., 2007). We found that DAO protein was less expressed
in the cerebellum, but DAO mRNA was highly expressed in
the cerebellum as compared to other regions studied, which
might indicate post-transcriptional regulation such as microRNA
(miRNA) mediated regulation. The miRWalk 2.0 database
(Dweep and Gretz, 2015) with prediction algorithms from four
different databases (miRWalk, miRanda, RNA22, Targetscan)
showed that there are around 327 predicted miRNA target
sites in the promoter region (miRWalk, miRanda, Targetscan),
three predicted miRNA target sites in the 5′UTR (miRWalk,
miRanda, RNA22), 74 predicted miRNA target sites in the
coding DNA sequence (CDS) (miRWalk, miRanda, RNA22,
Targetscan), and nine predicted miRNA target sites in the
3′UTR (miRWalk, miRanda, RNA22, Targetscan) of the DAO
gene. The interaction of these miRNAs with the DAO gene
in the cerebellum might be the reason for more DAO mRNA
and less DAO protein. However, these interactions have to be
confirmed experimentally. We measured DAO protein but not
the activity of DAO protein because the buffer used to isolate
proteins deactivated the DAO enzyme. Therefore, in our study,
we are unable to comment on the activity of DAO in different
brain regions. The DAO protein can be either in an active
[flavin adenine dinucleotide (FAD bound) or inactive (FAD
unbound) state; Caldinelli et al., 2009; Terry-Lorenzo et al., 2014].
Kapoor et al. (2006) showed that DAO activity was detected
in the human cerebellum but not in the human forebrain.
Moreover, a recent study by Sasabe et al. (2014) showed that
DAO activity was detected in the human hindbrain, midbrain,
spinal cord, and only in the white matter of the forebrain.
Therefore, DAO activity in the human forebrain is not yet very
clear.
DAOA is a primate-specific gene which shows a complex
alternative splicing pattern, and encodes a protein characterized
by a rapidly changing structure during evolution (Chumakov
et al., 2002). The DAOA gene and protein expression in
the human brain have not yet been fully characterized. We
detected DAOA protein using ELISA in all of the brain regions
studied. The human protein atlas detected DAOA protein in
the cerebellum and cerebral cortex using immunohistochemistry
(Uhlen et al., 2015). Kvajo et al. (2008) detected DAOA protein
in the human amygdala using Western blot. However, Benzel
et al. (2008) could not detect DAOA protein in the human
brain (cerebellum, amygdala, frontal cortex) using Western
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FIGURE 5 | Correlation between DAO (µg DAO/mg total protein) and DAOA protein expression (µg DAOA/mg total protein) in six regions of the
human post-mortem brain (A–F). Data is presented as scatter plots with linear fit and 95% confidence intervals. Correlation between DAO and DAOA protein
levels in different brain regions were assessed with the partial correlation test, controlled for age; p < 0.05 was taken as statistically significant (N: sample size,
r: correlation co-efficient).
blot. Studies showing DAOA mRNA expression in the human
brain are limited (Chumakov et al., 2002; Korostishevsky et al.,
2006). We were unable to detect DAOA mRNA in all the
brain regions studied using qRT-PCR, which is in line with
previous studies that used methods such as northern blotting,
qRT-PCR, and RNA sequencing (Benzel et al., 2008; GTEx
Consortium, 2015). The reason for detecting DAOA protein
but not DAOA mRNA in the human brain might be a tightly
regulated DAOA expression or extremely localized expression or
post-transcriptional regulation by RNA methylation. A previous
study suggested that undetectable DAOA mRNA in the human
brain might be because of RNA instability motif found in
the 5′UTR of DAOA gene (Benzel et al., 2008). There are
around 314 predicted miRNA target sites in the promoter
region (miRWalk, miRanda, Targetscan), five predicted miRNA
target sites in the 5′UTR (miRWalk, miRanda, RNA22), 317
predicted miRNA target sites in the CDS (miRWalk, miRanda,
Targetscan), and 70 predicted miRNA target sites in the 3′UTR
(miRWalk, miRanda, RNA22) of the DAOA gene as described
in the miRWalk 2.0 database (Dweep and Gretz, 2015) with
prediction algorithms from four different databases (miRWalk,
miRanda, RNA22, Targetscan). The interaction of these miRNAs
with the DAOA gene might be the reason for the variation of
DAOA protein expression in different brain regions. However,
the interactions of miRNA with the DAOA gene have to be
confirmed experimentally.
During brain development, there are critical and sensitive
periods during which the brain is more vulnerable to
environmental insults that can potentially lead to psychiatric
disorders (Meredith, 2015). In order to understand pathological
changes that occur in psychiatric disorders, it is important to
analyze the expression of risk genes for psychiatric disorders
in the normal brain across the lifespan. In our study, we
found that DAO mRNA levels were positively correlated with
age less than 2 years in the cerebellum and amygdala. Our
data is in agreement with previous studies of whole-genome
expression analysis in the developing brain which reported
that prenatal and neonatal periods are associated with a
rapid change of gene expression patterns in the brain as
compared to other age periods (Kang et al., 2011; Naumova
et al., 2013). During brain development and maturation,
synaptic plasticity varies significantly across different brain
regions, which might contribute to the brain region-specific
gene expression (Huttenlocher and Dabholkar, 1997; Caruana
et al., 2012). In this study, DAO expression was brain region
specific, indicating that DAO is differentially regulated across
hindbrain and forebrain regions. Interestingly, we found a
significant positive correlation between DAO and DAOA protein
in all the brain regions studied except for the frontal cortex.
This positive correlation between DAO and DAOA protein
might be because of the variability in density of particular
cell types in different brain regions. A recent in vitro study
showed that there is an interaction between DAO and DAOA
proteins (Birolo et al., 2016). Nonetheless, the effect of DAOA
protein on DAO is controversial. Chumakov et al. (2002)
reported DAOA to be an activator of DAO, but Sacchi et al.
(2008) reported DAOA to be a repressor of DAO. From our
finding, we are still unable to conclude regarding DAO and
DAOA interaction, but we could show their simultaneous
expression.
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DNA methylation has been widely acknowledged to be crucial
for normal brain development (Fan et al., 2001), and alterations
in DNA methylome in the human brain might contribute
to neuropsychiatric disorders (Illingworth et al., 2015). DNA
methylation can lead to both increases and decreases in gene
expression (Wagner et al., 2014). We found in silico that the
cerebellum was significantly more methylated than the frontal
cortex in most of the DAO and DAOA CpG sites which is
in line with previous studies (Davies et al., 2012; Hannon
et al., 2015; Illingworth et al., 2015). This finding might explain
the differential expression of DAO mRNA in the cerebellum
and frontal cortex. However, further studies are required to
understand the extent to which DNA methylation or other
epigenetic modifications affect the expression of genes important
for human brain function.
In this study, we attempted to carefully address confounding
factors such as PMI and gender that are inherent in human post-
mortem studies. Our study is the first study which measured
concomitantly DAO and DAOA protein levels in human post-
mortem brain using quantitative ELISA method. Nevertheless,
we were only able to measure total DAO protein but not
the DAO activity in different brain regions because of the
isolation procedure used. In our study, we had no post-
mortem samples between ages 2 and 20 years, therefore we
are unable to comment on alterations within this particular
developmental phase. We also do not have schizophrenia brain
samples to comment on regulation and expression of DAO
and DAOA mRNA and protein across different brain regions
in schizophrenia. DAO and DAOA are susceptibility genes for
schizophrenia and bipolar disorders. Both disorders are discussed
as neurodevelopmental disorders, and first symptoms often occur
before early adulthood, whereas the definitive onset of the
disorder is typically in early adulthood (Cacabelos and Martinez-
Bouza, 2011; Rapoport et al., 2012). Therefore, it is important
to investigate the regulation of these genes between 2 and
20 years in the normal human brain. Hence, future studies
in this age period would be useful to elucidate this question.
Another limitation of the study is that because of limited sample
size, it is not powered appropriately, particularly regarding the
effect of DAO and DAOA polymorphisms on their expression.
However, the strength of this study lies in the fact that we
extracted DNA, RNA, and total protein from the same tissue,
which allowed us to investigate concomitantly DAO and DAOA
expression in six different brain regions and across a wide range
of ages.
In summary, our results showed the regional expression of
DAO and DAOA with age in normal human post-mortem
brain samples. We detected DAOA protein, despite undetectable
DAOA mRNA levels in the human post-mortem brain.
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